Bioinstrumentation for evaluation of workload in payload specialists: results of ASSESS II

ASSESS II (Airborne Science/Spacelab Experiments System Simulation) was a cooperative NASA-ESA project which consisted of a detailed simulation of Spacelab operations using the NASA Ames Research Center CV-990 aircraft laboratory. The Medical Experiment reported on in this paper was part of the complex payload consisting of 11 different experiments. Its general purpose was to develop a technology, possibly flown on board of Spacelab, and enabling the assessment of workload through evaluating changes of circadian rhythmicity, sleep disturbances and episodical or cumulative stress. As parameters the following variables were measured: Rectal temperature, ECG, sleep-EEG and -EOG, the urinary excretion of hormones and electrolytes. The results revealed evidence that a Spacelab environment, as simulated in ASSESS II, will lead to internal dissociation of circadian rhythms, to sleep disturbances and to highly stressful working conditions. Altogether these effects will impose considerable workload upon Payload Specialists. It is suggested that an intensive pre-mission system simulation will reduce these impairments to a reasonable degree. The bioinstrumentation applied in this experiment proved to be a practical and reliable tool in assessing the objectives of the study.     

Space motion sickness medications: interference with biomedical parameters

The possibility that drugs administered to Skylab 3 (SL-3) and 4 (SL-4) crewmen for space motion sickness may have interfered with their biomedical evaluation in space was investigated. Healthy volunteers received combinations of Scopolamine/Dexedrine for four days in regimens similar to those used in these missions. Urine samples, heart rate, body temperature, mood and performance were analyzed for drug-related changes. Twenty-four hour urine samples were analyzed by the same procedures as those used to analyze the flight samples. Hormone concentrations determined included cortisol, epinephrine, norepinephrine, aldosterone and antidiuretic hormone (ADH). In addition, volume, specific gravity, osmolarity, sodium (Na), potassium (K), calcium (Ca), magnesium (Mg), chloride (Cl), inorganic phosphate, uric acid and creatinine were measured. Performance was not affected by the Scopolamine/Dexedrine. The drug combination increased daily mean heart rate (HR) significantly in all the subjects and daily mean rectal temperature (RT) in some of the subjects. A 2-4 hr phase shift in the HR circadian rhythm was also observed which indicates that internal circadian synchrony was disturbed by the drugs. Psychological and subjective evaluation indicated that the subjects could usually identify which days they were given the drugs by an increase in tension and anxiety, decreased patience, restlessness, decreased appetite, difficulty in sleeping and feelings of increased heart rate and body temperature. Urinary electrolytes were not changed significantly by the drug, but marked and significant changes occurred in urine volume and hormone excretion patterns. Scopolamine/Dexedrine caused consistent elevations in urinary cortisol and epinephrine and a transient elevation in ADH. Norepinephrine excretion was decreased, but there was no significant change in aldosterone excretion or in 24 hr urine volume. A comparison of these findings with the first four days of inflight data from the SL-3 and SL-4 missions leads to the conclusion that the dramatic increases in aldosterone excretion during the first three days of spaceflight probably can be directly attributed to weightlessness, whereas the antimotion sickness medication could have substantially contributed to the early increased excretion of epinephrine and cortisol during these missions.